BioAtla Reports Improved Survival Outcomes in NSCLC Patients with Mutated KRAS Treated with Mecbotamab Vedotin
Mec-V shows improved one-year survival in mKRAS NSCLC patients compared to wtKRAS, supporting further clinical trials.Quiver AI SummaryBioAtla, Inc. reported promising results for its treatment, Mecbotamab...
BioAtla, Inc. to Present Research on Mecbotamab Vedotin at IASLC 2024 Meeting
BioAtla will present research on Mecbotamab Vedotin at the IASLC meeting December 14, 2024, in Washington, DC.Quiver AI SummaryBioAtla, Inc., a clinical-stage biotechnology company specializing in Conditionally...
Michael Burry Cautiously Ups Alibaba, JD.com, Baidu Bets With Offsetting Hedges: Retail Doesn’t Share Big Short Investor’s Optimism
Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as...